Table 3. Cumulative events at 30-day, 6-month and 1-year follow-up.

Event	30-day follow-up n=13	6-month follow-up n=13	1-year follow-up</p> n=5
Primary safety endpoints
All-cause mortality	0 (0)	0 (0)	0 (0)
Myocardial infarction	0 (0)	0 (0)	0 (0)
Disabling stroke	0 (0)	0 (0)	0 (0)
Life-threatening bleeding	0 (0)	0 (0)	0 (0)
VARC-3 endpoints*
Valve-related mortality	0 (0)	0 (0)	0 (0)
All strokes	0 (0)	0 (0)	0 (0)
Neurological dysfunctions	0 (0)	0 (0)	0 (0)
All bleeding	0 (0)	0 (0)	0 (0)
Major vascular complications	1 (7.69)	0 (0)	0 (0)
Minor vascular complications	0 (0)	0 (0)	0 (0)
Cardiac complications	0 (0)	0 (0)	0 (0)
Permanent pacemaker implant	1 (7.69)	0 (0)	0 (0)
Bioprosthetic valve dysfunction	0 (0)	0 (0)	0 (0)
Structural valve deterioration	0 (0)	0 (0)	0 (0)
Reoperations/reinterventions on the study valve	0 (0)	0 (0)	0 (0)
Acute kidney injury	0 (0)	0 (0)	0 (0)
Major paravalvular leak (moderate or severe)	0 (0)	0 (0)	0 (0)
Major aortic regurgitation (moderate or severe)	1 (7.69)	1 (7.69)	0 (0)
Values are n (%). *Study endpoints are defined according to the VARC-3 guidelines16. VARC: Valve Academic Research Consortium